Levosimendan Shows Benefits in 84% of Patients in Small PH-HFpEF Trial

Levosimendan Shows Benefits in 84% of Patients in Small PH-HFpEF Trial

291793

Levosimendan Shows Benefits in 84% of Patients in Small PH-HFpEF Trial

Treatment with the investigational medication levosimendan was found to improve exercise tolerance, and some parameters related to heart function, in a small clinical trial of people with pulmonary hypertension and heart failure with preserved ejection fraction — a condition known as PH-HFpEF. In fact, 84% of patients in the trial’s initial lead-in phase responded to levosimendan based on prespecified criteria, according to Tenax Therapeutics, the company developing levosimendan in North America. “This is the first multi-center, randomized,…

You must be logged in to read/download the full post.